[Paper] ATTAIN-1 — an oral pill with no food restrictions is a bigger deal than the % suggests
Something I keep coming back to: ATTAIN-1 — an oral pill with no food restrictions is a bigger deal than the % suggests. Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something. Started keeping the trial identifiers straight in a note file because I kept…
Left up and flaired Trial Data. The publication is linked rather than the coverage, which is what we ask for.
Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.
Absolute or relative risk reduction?
open-label extensions are not the same evidence as the randomised phase
That is the 68-week readout, not the 72-week one. Different trial, different duration.
Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.
Same. A press release is a claim about a result; the publication is the result.
The press release said that; the publication says something more hedged. Worth reading both.
Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.